Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: The antigen scale.
Identifieur interne : 001136 ( Ncbi/Checkpoint ); précédent : 001135; suivant : 001137Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: The antigen scale.
Auteurs : Jody D. Berry [Canada]Source :
- Veterinary journal (London, England : 1997) [ 1090-0233 ] ; 2005.
Descripteurs français
- KwdFr :
- MESH :
- immunologie : Anticorps monoclonaux, Antigènes.
- usage thérapeutique : Anticorps monoclonaux.
- Animaux, Bioterrorisme, Humains, Maladies de l'animal, Maladies transmissibles émergentes, Protéines recombinantes, Recherche.
English descriptors
- KwdEn :
- MESH :
- chemical , immunology : Antibodies, Monoclonal, Antigens.
- prevention & control : Animal Diseases, Communicable Diseases, Emerging.
- chemical , therapeutic use : Antibodies, Monoclonal.
- Animals, Bioterrorism, Humans, Recombinant Proteins, Research.
Abstract
Many factors influence the choice of methods used to develop antibody to infectious agents. In this paper, we review the current status of the main technologies used to produce monoclonal antibodies (mAbs) from the B cells of antigen-sensitized animals. While companies are adopting advanced high-throughput methods, the major technologies used by veterinary and medical research laboratories are classical hybridoma fusion and recombinant library selection techniques. These methods have inherent advantages and limitations but have many common aspects when using immunized rodents. Laboratories with expertise in both methods of antibody development have a distinct advantage in their ability to advance mAb technology. New and re-emerging infectious threats in today's world emphasize the need for quality immunoreagents and the need to maintain expertise in mAb development. We provide examples of some common applications for mAb reagents used to identify pathogens such as the SARS-coronavirus (SARS-CoV), Bacillus anthracis, and foot-and-mouth disease (FMD) virus. We also outline a framework for investigators to make rational decisions concerning which method to use to develop mAbs based upon characteristics of the pathogen under study and the intended downstream application. Lastly, we provide parameters for the immunisation of mice and a classification system which describes the expected outcome for mAb development strategies when using classes of immunogens to generate mAbs with desired activities.
DOI: 10.1016/j.tvjl.2004.04.021
PubMed: 16129340
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002565
- to stream PubMed, to step Curation: 002565
- to stream PubMed, to step Checkpoint: 002548
- to stream Ncbi, to step Merge: 001136
- to stream Ncbi, to step Curation: 001136
Links to Exploration step
pubmed:16129340Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: The antigen scale.</title><author><name sortKey="Berry, Jody D" sort="Berry, Jody D" uniqKey="Berry J" first="Jody D" last="Berry">Jody D. Berry</name><affiliation wicri:level="1"><nlm:affiliation>National Centre for Foreign Animal Disease, Canadian Food Inspection Agency, 1015 Arlington Street, Winnipeg, MB, Canada R3E 3M4. berryjd@inspection.gc.ca</nlm:affiliation><country>Canada</country><wicri:regionArea>National Centre for Foreign Animal Disease, Canadian Food Inspection Agency, 1015 Arlington Street, Winnipeg, MB</wicri:regionArea><wicri:noRegion>MB</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16129340</idno><idno type="pmid">16129340</idno><idno type="doi">10.1016/j.tvjl.2004.04.021</idno><idno type="wicri:Area/PubMed/Corpus">002565</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002565</idno><idno type="wicri:Area/PubMed/Curation">002565</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002565</idno><idno type="wicri:Area/PubMed/Checkpoint">002548</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002548</idno><idno type="wicri:Area/Ncbi/Merge">001136</idno><idno type="wicri:Area/Ncbi/Curation">001136</idno><idno type="wicri:Area/Ncbi/Checkpoint">001136</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: The antigen scale.</title><author><name sortKey="Berry, Jody D" sort="Berry, Jody D" uniqKey="Berry J" first="Jody D" last="Berry">Jody D. Berry</name><affiliation wicri:level="1"><nlm:affiliation>National Centre for Foreign Animal Disease, Canadian Food Inspection Agency, 1015 Arlington Street, Winnipeg, MB, Canada R3E 3M4. berryjd@inspection.gc.ca</nlm:affiliation><country>Canada</country><wicri:regionArea>National Centre for Foreign Animal Disease, Canadian Food Inspection Agency, 1015 Arlington Street, Winnipeg, MB</wicri:regionArea><wicri:noRegion>MB</wicri:noRegion></affiliation></author></analytic><series><title level="j">Veterinary journal (London, England : 1997)</title><idno type="ISSN">1090-0233</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal Diseases (prevention & control)</term><term>Animals</term><term>Antibodies, Monoclonal (immunology)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antigens (immunology)</term><term>Bioterrorism</term><term>Communicable Diseases, Emerging (prevention & control)</term><term>Humans</term><term>Recombinant Proteins</term><term>Research</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps monoclonaux (immunologie)</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Antigènes (immunologie)</term><term>Bioterrorisme</term><term>Humains</term><term>Maladies de l'animal ()</term><term>Maladies transmissibles émergentes ()</term><term>Protéines recombinantes</term><term>Recherche</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antigens</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Antigènes</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Animal Diseases</term><term>Communicable Diseases, Emerging</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Bioterrorism</term><term>Humans</term><term>Recombinant Proteins</term><term>Research</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Bioterrorisme</term><term>Humains</term><term>Maladies de l'animal</term><term>Maladies transmissibles émergentes</term><term>Protéines recombinantes</term><term>Recherche</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Many factors influence the choice of methods used to develop antibody to infectious agents. In this paper, we review the current status of the main technologies used to produce monoclonal antibodies (mAbs) from the B cells of antigen-sensitized animals. While companies are adopting advanced high-throughput methods, the major technologies used by veterinary and medical research laboratories are classical hybridoma fusion and recombinant library selection techniques. These methods have inherent advantages and limitations but have many common aspects when using immunized rodents. Laboratories with expertise in both methods of antibody development have a distinct advantage in their ability to advance mAb technology. New and re-emerging infectious threats in today's world emphasize the need for quality immunoreagents and the need to maintain expertise in mAb development. We provide examples of some common applications for mAb reagents used to identify pathogens such as the SARS-coronavirus (SARS-CoV), Bacillus anthracis, and foot-and-mouth disease (FMD) virus. We also outline a framework for investigators to make rational decisions concerning which method to use to develop mAbs based upon characteristics of the pathogen under study and the intended downstream application. Lastly, we provide parameters for the immunisation of mice and a classification system which describes the expected outcome for mAb development strategies when using classes of immunogens to generate mAbs with desired activities.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Berry, Jody D" sort="Berry, Jody D" uniqKey="Berry J" first="Jody D" last="Berry">Jody D. Berry</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001136 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 001136 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:16129340
|texte= Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: The antigen scale.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:16129340" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |